TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02316626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous progesterone
Description: 25 mg daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 90 mg daily for 14 days
Study: NCT01599806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime - Avibactam ( CAZ-AVI)
Description: Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study: NCT02930954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed or gemcitabine plus carboplatin,
Description: doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab 7.5mg/kg intravenously per 3 weeks
Study: NCT02932579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Testing
Description: Saliva collection (5mL)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic Testing
Description: Saliva collection (5mL)
Study: NCT01599806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Description: Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
Study: NCT02194517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELKa
Description: ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
Study: NCT01709968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAGNOX 520®
Description: un-organic granular magnesium complex, composed of Magnesium Oxide \& Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Similarly looking placebo. Oral administration once daily for 4 weeks
Study: NCT01407848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline 0,9%
Description: nebulised 0,9% saline 4x/d for max.3 days
Study: NCT01902004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
Study: NCT01994317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: IV sedation dosing calculated by algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: IV sedation dosing calculated by standard care.
Study: NCT02375984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Patients will receive an IV adoptive transfer of at least 10\^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
Study: NCT01659268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation class
Description: The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation.
Study: NCT00434993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol Sulfate
Description: Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~* The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~* The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Bronchoalveolar Lavage (BAL)
Description: The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mini-Bronchoalveolar Lavage (BAL)
Description: The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first.
Study: NCT03858517

Intervention type: DEVICE
Intervention: ReUnion TSA System
Description: The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
Study: NCT00343564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-743921
Description: Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-743921
Description: Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
Study: NCT00644826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preventive home visit
Description: A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
Study: NCT02599311

Intervention type: DEVICE
Group type: OTHER
Intervention: transvaginal synthetic mesh
Description: transvaginal synthetic mesh

Intervention type: DRUG
Group type: OTHER
Intervention: Tolterodine
Description: Tolterodine tartrate can improve patients' LUTS.
Study: NCT04318054

Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.
Description: fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health.
Description: fibromyalgia patients consulting in Grenoble Alps University Hospital who will practice an ambulatory activity combining rehabilitation and therapeutic education, using an Intelligent Electric Bike for the Health during 8 weeks (2 times by week).
Study: NCT03645278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0532
Description: Ascending dose oral adminstration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ascending dose oral administration
Study: NCT00984594

Intervention type: OTHER
Group type: OTHER
Intervention: Primary injury site
Description: Autograft will be placed in the primary defect site.

Intervention type: OTHER
Group type: OTHER
Intervention: Backfill site
Description: Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
Study: NCT03841851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sub epithelial connective tissue graft
Description: * Local anesthesia will be injected intra-orally at the implant site.~* Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~* immediate temporization .~* subepithelial connective tissue graft from the palate
Study: NCT04498403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole 2%
Description: Crisaborole 2% ointment
Study: NCT01659866

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: 500 mg orally 2 hours before prostate biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Description: 1 double strength tablet orally 2 hours before the procedure and again 12 hours later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: 500 mg orally 2 hours before the procedure then again 12 hours later

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 500 mg intramuscularly 2 hours before the procedure
Study: NCT01659268

Intervention type: OTHER
Group type: OTHER
Intervention: Exhibition-dialogued class
Description: The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes.
Study: NCT01659866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: 2 mg/kg intramuscularly 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amikacin
Description: 5 mg/kg intramuscularly 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aztreonam
Description: 500 mg intramuscularly 2 hours before the procedure
Study: NCT02783209

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract surgery
Study: NCT00810030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sucrose
Description: VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is \>25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height \[m\] x height \[m\].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit.
Study: NCT01919606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
Study: NCT02654275

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive Intervention
Study: NCT01659866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem
Description: 500 mg intramuscularly 2 hours before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 2000 mg intravenously 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin
Description: 2 mg/kg intravenously 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amikacin
Description: 5 mg/kg intravenously 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aztreonam
Description: 2000 mg intravenously 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipenem
Description: 1000 mg intravenously 1 hour before the procedure
Study: NCT00927693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium (CAC) Scan
Description: A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
Study: NCT02958982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP3128
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
Study: NCT02534844

Intervention type: DRUG
Group type: OTHER
Intervention: Parts A/B: Adrabetadex
Description: 900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parts A/B: Sham Control
Description: No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
Study: NCT02352545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
Study: NCT02555748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Study: NCT02155894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease control, Telemedicine, doctor
Description: Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system.
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
Study: NCT02155894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease control, Telemedicine, nurse
Description: Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system.
Study: NCT03934541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPER-656 Liposome Vaccine
Description: Administered by intramuscular injection
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adavosertib
Description: adavosertib administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
Study: NCT03934541

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MPER-656 Liposome Vaccine
Description: Administered by intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MPER-656 Liposome Vaccine
Description: Administered by intramuscular injection
Study: NCT00648648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine administered at 1000 mg/m\^2 by IV infusion in a 28-day cycle.
Study: NCT03934541

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MPER-656 Liposome Vaccine
Description: Administered by intramuscular injection
Study: NCT03902041

Intervention type: DRUG
Intervention: Eltrombopag
Description: The patients will receive Eltrombopag treatment after transplantation
Study: NCT00418899

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).